临床试验/NCT05187026

NCT05187026Unknown不适用

Electrical Patient Reported Outcome of Prostate Cancer RadioTherapy

Helsinki University Central Hospital1 个研究点分布在 1 个国家目标入组 300 人开始时间: 2016年12月9日最近更新: 2022年1月26日

适应症

试验速览

阶段: 不适用
发起方: Helsinki University Central Hospital
入组人数: 300
试验地点: 1
主要终点: preference

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is an observational study where prostate cancer related PROMs (EPIC-26) is collected using two different methods (by paper questionnaires and electronically) and patient experience and preference is asked.

详细描述

Prostate cancer patients that are treated with radiation therapy for local prostate cancer receive EPIC-26 before treatment and during follow-up. EPIC-26 is collected both traditionally using paper questionnaires and electronically. Patients experience and preference for these are asked.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 100 Years（Adult, Older Adult）
性别: Male
接受健康志愿者: 否

入选标准

•cT1-4N0M0, gleason 6-10, PSA < 100, WHO ≤ 2 prostate cancer eligible for radiation therapy
•willing to complete EPIC-26 questionnaires both in paper and electronically
•willing to consent for the study

排除标准

•not able to complete EPIC-26 both in paper and electronically

结局指标

主要结局

preference

时间窗: through study completion, an average of 1 year

patient preference for type of questionnaire (paper versus electronic)

次要结局

QoL as measured using the validated EPIC-26 questionnaire(through study completion, an average of 1 year)

研究者

发起方

Helsinki University Central Hospital

申办方类型

Other

责任方

Principal Investigator

主要研究者

Antti Rannikko

assistant professor

Helsinki University Central Hospital

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

不适用

Prostate Cancer BiobankProstatic Neoplasms

NCT04024475Swiss Group for Clinical Cancer Research1,323

Unknown

1 期

MRI / Ultrasound Fusion With Contrast-Enhanced Ultrasound GuidanceProstatic Neoplasms

NCT02233725University of British Columbia50

招募中

不适用

Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate CancerProstatic Neoplasm

NCT06236789Yonsei University60

撤回

不适用

Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation ToxicityProstate Cancer

NCT04580667DiaCarta, Inc.250

撤回

不适用

Prostate Cancer Parameters for Patients Receiving Proton TreatmentProstate Cancer

NCT02110849Indiana University